Rhumbline Advisers Acquires 25,822 Shares of Hologic, Inc. (NASDAQ:HOLX)

Rhumbline Advisers raised its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 5.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 535,348 shares of the medical equipment provider's stock after acquiring an additional 25,822 shares during the period. Rhumbline Advisers owned approximately 0.24% of Hologic worth $33,068,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Venturi Wealth Management LLC raised its stake in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 260 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares in the last quarter. Smithfield Trust Co lifted its holdings in shares of Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 400 shares during the period. Finally, Raiffeisen Bank International AG acquired a new stake in shares of Hologic during the 4th quarter worth approximately $49,000. 94.73% of the stock is currently owned by institutional investors.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of Hologic stock in a transaction that occurred on Wednesday, May 7th. The shares were acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the acquisition, the director now directly owns 5,445 shares of the company's stock, valued at approximately $300,781.80. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 1.88% of the stock is owned by corporate insiders.

Hologic Trading Up 2.0%

NASDAQ:HOLX traded up $1.26 during mid-day trading on Friday, hitting $64.33. 2,267,875 shares of the company's stock were exchanged, compared to its average volume of 2,287,561. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $14.34 billion, a P/E ratio of 20.29, a PEG ratio of 2.14 and a beta of 0.54. The company has a 50 day simple moving average of $58.21 and a 200-day simple moving average of $65.54.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Hologic's revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.03 earnings per share. As a group, research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on HOLX shares. Evercore ISI decreased their price objective on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a research note on Friday, May 2nd. Leerink Partners downgraded Hologic from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Stephens lowered their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Royal Bank of Canada dropped their price objective on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Finally, Argus lowered Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Twelve research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $77.42.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.